Tesamorelin: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Tesamorelin is approved as a prescription drug (Egrifta) by both the FDA and Health Canada for a specific indication; the research-grade compound discussed for other applications in this guide is not approved by either regulator for those uses.

Last updated: July 2026

---

Tesamorelin occupies a genuinely unique position in this entire guide series: it’s the only growth hormone axis compound with real regulatory approval behind it — from Health Canada as well as the FDA. Everything else in this category — CJC-1295, Ipamorelin — reached some stage of development and stopped short. Tesamorelin made it all the way through, and that changes what can honestly be said about it.

Quick Facts

	
Class	GHRH analog
Receptor target	GHRH receptor, anterior pituitary
Administration	Subcutaneous, once daily, fasted
Typical effective range (community-reported)	1mg–2mg once daily
Evidence tier	Highest of any GH-axis compound in this guide series — full Phase 3 program, approved by both the FDA and Health Canada
Regulatory status	Approved by both the FDA and Health Canada (Egrifta), for HIV-associated lipodystrophy; other research uses are unapproved by either regulator
First approved	November 2010 (FDA); April 2014 (Health Canada)
Developed by	Theratechnologies Inc., a Montreal-based Canadian biopharmaceutical company

The Story So Far

Tesamorelin is a synthetic analog of GHRH 1-44 — the full 44-amino-acid sequence of human growth hormone-releasing hormone, modified at one end with a chemical group (trans-3-hexenoic acid) that protects it from the rapid enzymatic breakdown natural GHRH undergoes in the body. That single engineering change is what makes it viable as an actual drug rather than a signal that disappears in minutes.

Its development, by the Montreal-based Canadian biopharmaceutical company Theratechnologies, was driven by a specific clinical problem: HIV-associated lipodystrophy, a condition in which certain antiretroviral regimens cause excess visceral fat accumulation and body composition changes in HIV patients. The FDA approved Tesamorelin under the brand name Egrifta in November 2010, based on two Phase 3 randomized controlled trials totaling over 800 participants — a genuinely substantial clinical trial program, not a token study. Health Canada followed with its own approval in April 2014, and a second presentation (the 1mg/vial format) in March 2015 — meaning this compound has a real, direct regulatory approval in Canada specifically, developed by a Canadian company, rather than being a foreign pharmaceutical with no domestic status at all. That’s a genuinely different picture than most other compounds in this guide series, and worth knowing plainly: Tesamorelin, unlike Semax, BPC-157, TB-500, CJC-1295, or Ipamorelin, has an actual, legitimate Canadian prescription pathway through Egrifta, for its approved indication specifically.

The pivotal trial, published by Falutz and colleagues in the New England Journal of Medicine in 2007, found that six months of daily tesamorelin selectively reduced visceral abdominal fat and improved lipid profiles in HIV patients, without meaningfully worsening blood sugar control — a real, positive, well-powered clinical result.

The formulation has continued to evolve well past that original approval. Egrifta SV, a simplified vial format, was approved in 2019. The drug was reclassified from a New Drug Application to a Biologics License Application in 2020 — a regulatory technicality, but one that reflects its status as a genuine biologic rather than a small-molecule drug. Most recently, in March 2025, the FDA approved a new formulation — Egrifta WR — using a 1.28mg dose reconstituted weekly rather than daily, while remaining bioequivalent to the original 2mg daily formulation and requiring less than half the injection volume. It became commercially available in September 2025. This is a genuinely current, ongoing pharmaceutical product — not a compound whose development stalled years ago the way CJC-1295’s and Ipamorelin’s did.

Alongside its approved use, tesamorelin has increasingly been prescribed off-label — through compounding pharmacies and wellness-medicine practices — for general visceral fat reduction, body composition, and, more recently, cognitive support in aging adults, well beyond the HIV-lipodystrophy population its approval actually covers. Public search interest in tesamorelin grew substantially through late 2025 and early 2026, a pattern that closely mirrors what happened with semaglutide’s mainstream breakout a few years earlier, just at a smaller scale.

What It Actually Does

Tesamorelin binds to GHRH receptors on the pituitary gland, triggering pulsatile release of the body’s own growth hormone — the same fundamental mechanism CJC-1295 uses. Its protective chemical modification extends its functional activity enough to produce a clean, reasonably short-acting pulse profile without requiring the kind of albumin-binding extension CJC-1295’s DAC version relies on.

The clinical trial data behind its approval points to a specific strength: reducing visceral fat specifically, rather than general body composition change broadly. This distinction matters because visceral fat — the fat surrounding internal organs — carries a different metabolic risk profile than subcutaneous fat, and it’s the specific outcome tesamorelin’s approved indication and its strongest trial data both center on.

What the Research Shows

This is the one growth hormone axis compound in this guide series where the evidence base doesn’t need extensive caveats about mismatched formulations or unrelated trial indications — the trial data was generated using essentially the same drug, for the purpose it’s approved for.

The foundational trial, Falutz et al. (2007, New England Journal of Medicine), found that tesamorelin selectively reduced visceral adipose tissue and improved lipid profiles over six months in HIV-infected adults with lipodystrophy, with the safety and efficacy data from that program and a companion trial — over 800 participants combined — supporting the original 2010 approval. Later work, including a trial led by Stanley published in JAMA, confirmed reductions in both visceral fat and liver fat specifically, extending the evidence into metabolic liver health.

Phase 3 extension data documented safety through 52 weeks of continuous use, and real-world clinical use has extended considerably longer than that for many patients. The main long-term safety signal worth knowing: about 5% of tesamorelin users developed HbA1c levels in the diabetic range during trials, compared to 1% on placebo — a real, monitorable effect on glucose metabolism, not a theoretical concern. No treatment-related deaths or serious cardiovascular events were reported across the clinical trial program.

A smaller, separate placebo-controlled study in non-HIV adults with abdominal obesity also found meaningful visceral fat reduction over 26 weeks — a genuinely interesting signal for broader metabolic applications, but this is a single, smaller study, and it’s considerably less established than the HIV-lipodystrophy indication tesamorelin actually holds approval for. The gap between “approved indication” and “commonly discussed off-label use” is real here, and it’s worth keeping that distinction in view rather than treating the strength of the HIV-lipodystrophy data as if it automatically extends to general visceral fat reduction in a broader population.

How It Compares

Tesamorelin completes the growth hormone axis category alongside CJC-1295 and Ipamorelin. For the full three-way comparison, see our CJC-1295 guide. What sets Tesamorelin apart specifically:

	Tesamorelin	CJC-1295 (no DAC)	Ipamorelin
Receptor target	GHRH receptor	GHRH receptor	GHSR (ghrelin) receptor
Human trial history	Full Phase 3 program, 800+ participants; approved by FDA and Health Canada	Phase 1 PK data (DAC version only)	One completed Phase 2 RCT — for gut motility, not GH outcomes; failed primary endpoint
Regulatory status	Approved (Egrifta) by both the FDA and Health Canada, actively marketed	Not approved; FDA compounding status in flux	Not approved; FDA compounding status in flux
Best documented use	Visceral fat reduction, specifically in HIV-associated lipodystrophy	General GH-axis stimulation; typically stacked with Ipamorelin	Selectivity advantage over older GHRPs; typically stacked with CJC-1295
Manufacturing standard	cGMP, audited by both FDA and Health Canada	Research-grade, no standardized manufacturing oversight	Research-grade, no standardized manufacturing oversight

The honest positioning across all three: if formal clinical evidence and regulatory backing matter most to you, Tesamorelin is simply in a different category than the other two — it’s an actively manufactured pharmaceutical with a real approval from both the FDA and Health Canada, not a research compound. CJC-1295 and Ipamorelin remain far more commonly used in community research contexts, largely due to cost and accessibility rather than a claim that the evidence favors them over Tesamorelin.

Who Shouldn’t Use This

Because Tesamorelin holds genuine approval from both the FDA and Health Canada, its contraindications are drawn from an actual approved drug label — not inferred from preclinical data the way they are for CJC-1295 and Ipamorelin.

• Active malignancy or history of malignancy. A labeled contraindication, given the IGF-1 elevation associated with GH axis stimulation generally.
• Pituitary tumor, or history of pituitary surgery or radiation. A labeled contraindication, since the compound works through direct pituitary receptor activation.
• Pregnancy. A labeled contraindication.
• Known hypersensitivity to tesamorelin or mannitol (an inactive ingredient in the approved formulation).

Additionally, given the documented HbA1c effect in clinical trials, anyone with pre-diabetes or existing glucose regulation concerns should discuss tesamorelin specifically with a healthcare provider and expect regular monitoring — this isn’t a theoretical caution, it’s a labeled, quantified finding from the approval trials themselves.

Common Myths, Addressed

“Tesamorelin’s approval means it’s proven for general anti-aging and fat loss.” Not quite. The approval and the strongest trial data are specific to visceral fat reduction in HIV-associated lipodystrophy. The broader off-label uses it’s increasingly prescribed for — general body composition, cognitive support — have thinner, less established evidence behind them, even though they’re a common part of current off-label practice.

“Since it’s FDA-approved, tesamorelin from any source is the same quality.” Only the branded, prescription pharmaceutical (Egrifta, in its current WR formulation in the US, or the Health Canada-approved presentations available here) is manufactured under audited cGMP standards. Research-grade tesamorelin sold outside that pharmaceutical supply chain is a different product in a different regulatory category, regardless of the underlying molecule being the same.

What Researchers Are Actually Experiencing

Because Tesamorelin has genuine clinical trial data behind it, community-reported experience here can actually be checked against a real evidence base more directly than for CJC-1295 or Ipamorelin.

The same fasting and timing principles that apply to CJC-1295 and Ipamorelin apply here — administering in a properly fasted state supports the GH pulse the compound is trying to produce. Joint pain, peripheral edema, and mild muscle aches are the most commonly discussed side effects, directly consistent with what the clinical trials themselves documented, rather than being purely a community-only observation.

Researchers specifically interested in visceral fat as an objective — rather than general body composition or recovery — are the ones who most consistently gravitate toward Tesamorelin over CJC-1295 or Ipamorelin, reflecting its more targeted, better-documented use case.

This section reflects patterns commonly discussed across community research spaces, cross-referenced against a genuine clinical evidence base for this specific compound. Individual experience still varies.

The Practical Basics

Research Ranges

Protocol	Research Range	Frequency
Standard (matches approved dose)	1–2mg	Once daily, subcutaneous, fasted
Conservative start	500mcg–1mg	Once daily, building toward standard range

The approved pharmaceutical dose is 2mg daily (or the bioequivalent 1.28mg in the newer weekly-reconstitution WR formulation). Community research protocols commonly use 1–2mg once daily, with some researchers starting lower and building up.

Worked Dose Math

At 20mg/mL (a 40mg vial — standard 3mL vial capacity — reconstituted with 2mL BAC water, leaving comfortable headroom):

• 1mg → 0.05mL → 5 units
• 2mg → 0.1mL → 10 units

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe.

Vial Planning

A 40mg vial at 20mg/mL gives you 40mg total. At a steady 1mg/day, that’s 40 days per vial. At 2mg/day, 20 days.

Reconstitution and Storage — The Short Version

Research-grade tesamorelin reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days. For the complete process, see our dedicated reconstitution and storage guide. Note this differs from the approved pharmaceutical formulations, which have their own specific manufacturer reconstitution instructions.

Sourcing

Nothing tesamorelin-specific beyond the general picture for research-grade product — see our full guide on reading a Certificate of Analysis and vetting a vendor. Worth noting directly: the legitimate, approved version of this compound — Egrifta — is available in Canada by prescription through a licensed pharmacy, for its approved indication. Any research-vendor product is, by definition, a different regulatory category entirely, regardless of how it’s marketed.

Administration

Subcutaneous injection, once daily, fasted — bedtime or morning both used in community protocols, with the same fasting-window logic that applies to CJC-1295 and Ipamorelin.

Best Practices

• Monitor glucose markers if you’re running this for any extended period — the HbA1c effect is a documented, quantified finding from the approval trials, not a theoretical concern.
• Protect your fasting window, consistent with the other GH-axis compounds in this category.
• Be specific about your objective. If visceral fat reduction specifically is the goal, Tesamorelin’s evidence base is the most directly relevant of the three GH-axis compounds in this guide series.
• Track your protocol from day one — dose, timing, and observed effects, at minimum.

Common Mistakes to Avoid

• Assuming the HIV-lipodystrophy trial data extends automatically to general population use — the strongest evidence is specific to that population and that outcome.
• Skipping glucose monitoring during an extended protocol, given the documented HbA1c signal.
• Confusing research-grade tesamorelin with the approved pharmaceutical — they may share a molecule, but not a manufacturing standard or regulatory status.
• Not recording the reconstitution volume, turning every dose calculation into a guess.

What Happens If You Stop

Unlike CJC-1295 and Ipamorelin, Tesamorelin actually has real trial data addressing what happens with discontinued or interrupted use, since its Phase 3 program studied outcomes over extended, continuous administration. Visceral fat reduction achieved during treatment is generally understood to require continued administration to maintain, consistent with the broader pattern seen across GH-axis and GLP-1 compounds alike in this guide series — the underlying condition being addressed doesn’t resolve permanently, so the intervention’s effects are tied to continued use rather than producing a lasting, self-sustaining change.

What to Expect, Week by Week

• Weeks 1–4: Joint discomfort and mild fluid retention, where reported, tend to appear early and are generally described as manageable.
• Weeks 5–12: This is roughly the window the pivotal clinical trials began showing measurable visceral fat reduction, though individual results vary.
• Week 26 (trial endpoint): The Falutz et al. trial’s primary measurement point, showing the visceral fat and lipid improvements that supported approval — a genuinely useful benchmark for what a full research cycle looks like with this specific compound.

Individual timelines vary, but this pattern is grounded in real trial data more directly than the equivalent sections for CJC-1295 or Ipamorelin.

Combining With Other Compounds

Tesamorelin paired with Ipamorelin is a documented alternative to the more common CJC-1295/Ipamorelin combination, chosen specifically by researchers who want Ipamorelin’s complementary GHSR-pathway activation alongside Tesamorelin’s more targeted, better-evidenced visceral fat profile rather than CJC-1295’s broader, less clinically-validated GHRH-pathway activity.

Common Questions

Is Tesamorelin actually approved, or is that misleading marketing? It’s genuinely approved — under the brand name Egrifta, by both the FDA and Health Canada, most recently updated with a new US formulation (Egrifta WR) in March 2025. It was developed by a Canadian company, Theratechnologies, and has held Health Canada approval since 2014. That’s a real, current, actively-marketed pharmaceutical with a legitimate domestic prescription pathway, not just a US-only drug.

If it’s approved in Canada, why do people source it from research vendors instead of a pharmacy? Cost and the prescription requirement are the main reasons — Egrifta requires a prescription for a specific labeled indication, and off-label prescribing plus the branded price point make research-vendor sourcing attractive to some researchers, though that product exists in a completely different regulatory and quality-assurance category than the approved pharmaceutical.

Does Tesamorelin’s approval cover general anti-aging or fat-loss use? No — the approval and the strongest trial data are specific to visceral fat reduction in HIV-associated lipodystrophy. Broader off-label use has thinner evidence behind it.

How does it compare to CJC-1295 and Ipamorelin in terms of trust? It’s simply better-evidenced — a real Phase 3 program, an actual approval, and cGMP-audited manufacturing for the branded product. CJC-1295 and Ipamorelin both have legitimate underlying pharmacology, but neither has completed human efficacy trials supporting their most common current research uses.

Before You Start

A quick checklist to run through before your first dose:

• Confirmed none of the labeled contraindications (active malignancy, pituitary tumor/history, pregnancy) apply to you
• Planned for glucose monitoring if running an extended protocol
• Planned your fasting window around your injection timing
• Have a tracking method ready for dose, timing, and observed effects
• Clear on whether your objective (visceral fat specifically vs. general GH-axis effects) actually matches this compound’s best-documented use

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Dose	Frequency
Conservative start	500mcg–1mg	Once daily
Standard (matches approved dose)	1mg–2mg	Once daily, fasted

Where to Go From Here

• The Growth Hormone Axis Group — CJC-1295, Ipamorelin, and Tesamorelin compared in full
• CJC-1295: The Complete Guide
• Ipamorelin: The Complete Guide
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here outside its approved use to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.